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of adverse events (NAE); extrapyramidal symptoms (EPS); weight gain (WG); and 
sexual dysfunction (SD). The transition probabilities amongst health states were 
estimated from two different meta-analysis of clinical trials and from a retrospective 
Spanish study. The health care costs associated to each health state were obtained 
from a published Spanish study. It was used the minimum acquisition cost per mg. of 
the mean daily dose, for each AA, which is regarded as a relevant efﬁ ciency criterion 
in Hospital Pharmacy Departments. The time horizon applied in the analysis was 12 
months. a probabilistic sensitivity analysis was performed for all the variables involved 
in the analysis via Monte Carlo simulations. All costs were inﬂ ated to 2009 costs using 
Spanish Health System pay and prices index. RESULTS: In comparison with OLA, the 
treatment with ARI generates annual average cost savings per patient of c−688.70 ± 
21.69 (CI 95% −614.52; −729.18). In the most unfavourable scenario for ARI, that in 
which we assumed that ARI may have a similar rate of sexual dysfunction than that of 
quetiapine (i.e. the lowest rate amongst AA) the costs savings per patient would be 
c–270,94 ± 17,11 (CI 95% −237,20; −303,48). CONCLUSIONS: The results of this 
analysis show that patients treated with aripiprazole demonstrate lower adverse events 
costs in comparison to olanzapine. This difference may generate signiﬁ cant cost 
savings to the Spanish health system in the treatment of patients affected by bipolar 
disorders. The robustness of the results was tested via a probabilistic sensitivity 
analysis.
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OBJECTIVES: Real-world treatment patterns and health care resource utilization for 
patients with GAD in the United States are not fully deﬁ ned. METHODS: Data from 
the 2003–2007 Thomson Reuters MarketScan® Commercial Claims and Encounters 
and Medicare Supplemental and Coordination of Beneﬁ ts databases were utilised for 
analysis. For the current analysis, participants with a diagnosis of GAD (ICD-9 CM 
300.02) between January 1, 2004 and December 31, 2006 were included. The sample 
was divided into the following ﬁ ve subgroups: patients receiving non-pharmacological 
treatment, ﬁ rst-line therapy only, ﬁ rst-line + augmentation within 90 days of index 
prescription, ﬁ rst-line + switch within 90 days of index prescription and second-line 
therapy only. Additionally, GAD patients were compared with healthy controls 
without GAD or other mental health conditions. RESULTS: In total, 23,553 GAD 
patients (mean age range: 41.6–48.1 years; 56.1–68.6% female across the ﬁ ve groups) 
were included (non-pharmacological, n = 7055; ﬁ rst-line only, n = 6538; ﬁ rst-line + 
augmentation, n = 903; ﬁ rst-line + switch, n = 1953; second-line only, n = 7104). 
Paroxetine was the most commonly used ﬁ rst-line treatment at index (ﬁ rst-line cohorts: 
48%, 42%, 41%, respectively). In the second-line only cohort, a benzodiazepine 
(37%) or second-line SSRI/SNRI (27%) were the most commonly used agents at index. 
Benzodiazepines were the most commonly prescribed agents for augmentation of, or 
switching from, ﬁ rst-line treatments (augmentation 52%, switch 44%). Overall, GAD 
patients had higher health care utilization and signiﬁ cantly higher total health care 
costs versus healthy controls (mean per patient: $8058 vs. $2938, P < 0.0001). On 
average, GAD patients incurred an additional $425/month in direct health care costs 
in the 1-year post-index period versus healthy controls. CONCLUSIONS: The real-
world management of GAD is both complex and costly. Paroxetine was the most-
widely used ﬁ rst-line treatment for GAD. Benzodiazepines were the most widely used 
agents for augmentation of, or switching from, ﬁ rst-line treatments, and for second-
line therapy. Total health care costs were 2.7 times higher for GAD patients compared 
with healthy controls.
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OBJECTIVES: There is a paucity of published evidence estimating the economic and 
humanistic burden of illness in GAD. We report results of a retrospective database 
analysis examining the burden of GAD in Europe. METHODS: Data were derived 
from the European (France, Germany, UK, Italy, Spain) National Health and Wellness 
Survey database for 2008. The database captures information from adults (≥18 years) 
and is representative of the adult population in each country. Respondents reporting 
a diagnosis of GAD were propensity-score matched 1:1 to non-GAD controls on 
country, age, gender and employment status. Data were extracted on GAD medication 
use, resource utilization (emergency room visits, hospitalizations and health care 
provider visits) and work productivity (using the Work Productivity and Activity 
Impairment questionnaire) to calculate direct and indirect costs. Health-related quality 
of life (HRQoL) was derived using SF-12 mental and physical summary scores. Utili-
ties were derived from SF-6D preference scores and used to calculate cost per quality-
adjusted life-year (QALY). RESULTS: Of 53,524 respondents, 3,669 were assigned 
to the GAD group. GAD respondents accrued considerably higher direct (medication 
and health care resources) plus indirect (work productivity loss) costs (per person/
year) versus controls across pooled European countries (c5,308.80 vs. c2,441.10; P 
< 0.0001) and for each country (France c6,083.70 vs. c2,896.30; Germany c12,797.00 
vs. c4,876.10; UK c4,021.70 vs. c2,011.20; Italy c3,514.50 vs. c1,869.60; Spain 
c5,051.70 vs. c1,954.80; P < 0.0001 vs. controls within each country). Direct costs 
were driven by hospitalizations and psychologist/psychiatrist visits. Total costs 
increased with GAD severity from c4,094.00 for respondents with mild GAD to 
c7,753.10 for those with severe GAD. HRQoL was signiﬁ cantly poorer for GAD 
versus non-GAD respondents (P < 0.0001). Costs/QALY increased with GAD severity 
from c6,795 for mild GAD to c15,286 for severe GAD. CONCLUSIONS: The eco-
nomic and humanistic burden of illness of GAD across Europe is considerable and 
increases with the severity of disease.
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OBJECTIVES: Data concerning costs of patients with Attention deﬁ cit/hyperactivity 
disorder (ADHD) are scarce in Germany. Aim of this claims data analysis was to 
examine the costs of ADHD from the perspective of the statutory health insurance. 
METHODS: Nation-wide claims data of a major statutory health insurance fund was 
used to evaluate the overall and ADHD-related costs of ADHD-patients in 2008. All 
costs for outpatient care, inpatient care, pharmaceuticals, rehabilitation, occupational 
therapy as well as devices and aids, and sick leave payments were analyzed. To cal-
culate ADHD-related costs the overall health care costs of the identiﬁ ed ADHD-
patients were compared to an age and gender matched control group. RESULTS: 
Based on the used identiﬁ cation algorithm 30,264 ADHD-patients were identiﬁ ed. 
Mean overall costs of c3802 in the year 2008 were incurred from the health insurance 
perspective. c1704 (45%) were incurred by occupational therapy as well as devices 
and aids, and c779 (20%) were due to inpatient care; c751 (20%) resulted from 
outpatient care. Costs for pharmaceuticals were c483 (13%) and for rehabilitation 
were c35 (≤1%). Costs for sick leave payments came to c50 (1%). The matched 
control group contains 404,565 patients. Compared to this control group the incre-
mental mean costs of ADHD-patients were EUR 2,744. EUR 1,214 of these resulted 
from occupational therapy as well as devices and aids, c586 from inpatient care and 
c517 from outpatient care. Mean additional costs for pharmaceuticals in the ADHD-
group were c367. CONCLUSIONS: The major cost driver in ADHD from a health 
insurance perspective in Germany is occupational therapy as well as devices and aids.
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OBJECTIVES: To investigate the burden of depression in the Swiss population. The 
costs for the management of depressive patients will be analyzed for different severity 
classes of disease, based on the Hamilton depression rating scale, over a period of 12 
months following diagnosis. METHODS: A prospective, multicentre, non-interven-
tional study in psychiatrist practices was carried out. Patients who have been diag-
nosed with depression in the last three years were included. Patient’s characteristics 
and resource utilization in the ﬁ rst twelve months after diagnosis were collected. Costs 
analysis, subdivided in direct and indirect costs, was performed for three depression 
classes (mild, moderate, severe), according to the Hamilton depression score (HAMD-
17). Costs were also extrapolated to the national level. RESULTS: A total of 556 
patients were included. Hospitalization and hospitalization days were directly corre-
lated with disease severity (P < 0.001). Medical resource utilization linked to depres-
sion and antidepressant treatments were also correlated to disease status. Severe 
patients reported a signiﬁ cantly higher number of workdays lost and were signiﬁ cantly 
more often in disability insurance. Total direct costs per person, mainly due to hos-
pitalization costs, were CHF 4,823 for mild, CHF 13,251 for moderate, and CHF 
22,138 for severe depressions. Indirect costs, mainly due to workdays lost, resulted in 
CHF 11,892 for mild, CHF 17,267 for moderate, and CHF 22,710 for severe depres-
sions. Extrapolation at national level resulted in a total burden of about CHF 11 
billion. CONCLUSIONS: The burden of depression in Switzerland was estimated to 
be around CHF 11 billion. Costs of depression were directly related to disease severity. 
However, since many depressions remain unreported and since this analysis only 
included individuals between 18 and 65 years of age, it is reasonable to suppose that 
the total burden of depression may be even greater.
PMH19
BURDEN OF ILLNESS OF TREATMENT RESISTANT DEPRESSION
McInnis MM1, Halseth MJ2, Cyr P1, Howland RH3, Bockstedt Santiago L2, Goss T1
1Boston Healthcare Associates, Inc., Boston, MA, USA; 2Medtronic, Inc., Minneapolis, MN, 
USA; 3University of Pittsburgh School of Medicine Western Psychiatric Institute and Clinic, 
Pittsburgh, PA, USA
OBJECTIVES: Major depressive disorder (MDD) is a leading cause of disability, 
morbidity, and mortality worldwide. The lifetime prevalence in the US is 17%. Treat-
ment resistant depression (TRD) is generally deﬁ ned as failure to achieve remissions 
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despite adequate treatment. About 30% of patients do not achieve remission after 4 
different antidepressant treatment trials (Rush et. Al., 2006). a few studies have 
examined the economic burden of TRD, but none have investigated the cost associated 
with more chronic and extensive forms of TRD characterized by non-response to four 
or more treatment trials. The objective of this study is to compare the direct medical 
expenditures of TRD patients to chronic MDD patients. METHODS: Patients with 
chronic MDD (deﬁ ned as 2 or more years of continuous treatment) and patients with 
very severe TRD (deﬁ ned as switching, augmentation, or addition of at least four 
qualifying therapies) were identiﬁ ed in the PharMetrics Patient-Centric Database. 
Medical resource utilization (MRU) and payer costs per patient per year enrolled in 
the plan were compared. Patients were matched on duration of enrollment, length of 
depression, medications taken, and age. Statistical signiﬁ cance was assessed using 
Student’s t-tests. RESULTS: The average medical expenditures per TRD (n = 31,803) 
patient per year enrolled was $12,260 compared to $7,619 for non-TRD chronic 
MDD patients (n = 50,092) (p < 0.001), representing 60.9% higher costs per year. 
The differences in annual medical expenditures per TRD patient were primarily driven 
by higher medical and pharmacy MRU (number of services per patient) relative to the 
chronic MDD group (70.3 vs. 107.6, p < 0.001). CONCLUSIONS: Our results dem-
onstrate that TRD patients accrued signiﬁ cantly higher per patient medical costs than 
MDD patients due to higher medical resource use. These ﬁ ndings suggest that more 
effective non-pharmacological alternative interventions are needed.
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OBJECTIVES: Data concerning impact and costs of hospitalization in patients with 
schizophrenia are scarce in Germany. Aim of this claims data analysis was to examine 
the impact and costs of hospitalization in schizophrenia from the perspective of a 
major statutory health insurance fund. METHODS: A nation-wide database was used 
to evaluate the impact and related costs of hospitalization in schizophrenia (ICD-10 
F20.x) between 2004 and 2006. All hospitalised patients were identiﬁ ed based on 
claims data and schizophrenia related costs for outpatient care, inpatient care, medica-
tions, rehabilitation, occupational therapy, and sick leave payments were analyzed 
before, during and after the hospitalization. RESULTS: Data from 4126 hospitalised 
patients were available, with 46% being female and a mean age of 42 years. Mean 
length of the index hospitalization was 45.9 days and mean health insurance costs of 
c9366 incurred during the index hospitalization. In the 3 months before the index 
hospitalization, average costs of c297 and in the 3 months after the index hospitaliza-
tion costs of c2322 incurred for outpatient care, inpatient care, medications, rehabili-
tation, occupational therapy, and sick leave payments. 42.5% of the patients had at 
least one rehospitalization after the index hospitalization and mean costs of c8710 
incurred during the ﬁ rst rehospitalization. In the 4 weeks before the ﬁ rst rehospitaliza-
tion average costs of c1310 and in the 3 months after the rehospitalization costs of 
c2834 incurred. With any further rehospitalization costs for the inpatient care itself 
are decreasing slightly but overall costs for schizophrenia related medical care before 
and after the event are increasing. CONCLUSIONS: Impact and costs of hospitaliza-
tion in schizophrenia are signiﬁ cant, especially if the costs before and after hospitaliza-
tion were taken into account. Rehospitalizations are a frequent event in schizophrenia 
care with high impact on costs. Further studies including the predictors of hospitaliza-
tion are needed.
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OBJECTIVES: To investigate the health care resource utilization and costs for Swedish 
bipolar disorder patients. METHODS: Registry data on socio-demographics and 
disease-related resource use during 2006–2008 was collected for 1846 patients with 
bipolar disorder. Health care visits and hospitalizations were obtained from the 
Northern Stockholm psychiatric clinic, while data on pharmaceuticals and sick leave 
were obtained from the national pharmaceutical registry and the Swedish social insur-
ance agency, respectively. Community care data was obtained from the Swedish 
quality registry for bipolar disorder (BipoläR). Indirect costs were valued according 
to the human capital method. Costs across mood episodes (manic, depressive, and 
unspeciﬁ ed) as well as remission were calculated. a patient for which >70 days had 
passed since the last new episode or inpatient visit, was deﬁ ned as being in remission. 
RESULTS: The mean annual cost per patient with bipolar disorder was estimated at 
c24,300 (SEK 242,810) in 2009 prices, of which 23% represented direct treatment 
costs. The costs per month for active bipolar disorder were c6800 during depression, 
c6300 during mania, EUR 6,100 during unspeciﬁ ed episodes, and c1500 for patients 
in remission. a patient who was not hospitalized during 2006–2008 generated a mean 
annual cost of c18,900, whereas a patient who was hospitalized at least once every 
year 2006–2008 generated mean annual costs of c67,600. CONCLUSIONS: Societal 
costs for bipolar disorder were more than 3.5 times higher for patients who were 
admitted at least once per year in 2006–2008 compared to those who were not hos-
pitalized. Monthly costs during a depressive or manic episode were more than 4 times 
higher than during remission. Attempts to prevent mood episodes by means of effective 
treatment may not only decrease patient suffering, but also have the potential to 
dramatically reduce the societal cost of illness.
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OBJECTIVES: Rising life expectancy is associated with increasing prevalence of 
dementia in European countries. With progressing disease severity patients’ call on 
health care services and social support grows. Several studies stress the burden 
imposed on family members caring for dementia-patients. However, empirical data 
assessing the economic value of informal care compared to health insurance expendi-
tures is scarce. Within the cluster-randomized IDA study health care service utilization 
and informal caregiving time were assessed for 383 community living individuals 
suffering from mild to moderate dementia. METHODS: To examine costs from a 
health insurance perspective administrative data on all types of services provided were 
collected and valued with corresponding administrative prices over a three-year 
period. Patients’ caregivers reported in yearly interviews the hours daily dedicated to 
the patient in care and supervision. The time provided for informal caregiving was 
valued by applying hourly wages of a nursing service and a domestic help respectively. 
Total costs and cost components were calculated from societal perspective and payers’ 
point of view and analyzed by relevant subgroups. RESULTS: Caring for a home-
dwelling dementia-patient amounts annually to around c47.000 from societal perspec-
tive with informal care covering nearly 80% of this sum. For a patient with moderate 
dementia values assigned to informal care are approximately 70% higher than for a 
person with mild dementia. Health insurance has to spend c10,000 for an average 
dementia-patient per year, with services for long-term care representing the most costly 
part. CONCLUSIONS: Informal care is the major cost component in care for demen-
tia, and it is strongly rising with disease progression. Changes in family structures and 
traditional living arrangements thus pose an enormous challenge regarding the future 
organization of dementia care. To maintain today’s care-setting, concepts fostering 
community-based dementia care and support to family caregivers need to be further 
developed.
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OBJECTIVES: Literature on the costs of community support programs is scant. Beat 
the Blues (BTB) is a home support program for depression which involves trained 
social workers who meet with participants to identify care management concerns, 
make referrals and linkages, provide depression education, develop tailored action 
plans to accomplish identiﬁ ed behavioral goals and enhance engagement in pleasurable 
activities, and teach stress reduction techniques for managing daily stressors (e.g., deep 
breathing). The primary objective of this study is to assess the cost of implementing 
BTB in African American elders with depressive symptoms. METHODS: The cost 
analysis is piggybacked onto the parent BTB trial, which employs randomized two-
group experimental design (treatment vs. control). Candidates are screened twice for 
depressive symptoms (PHQ-9 score > 5) to determine eligibility. Participants are 
randomly assigned to intervention or waitlist control. BTB is administered over 4 
months with assessments in both groups at baseline and 4-months. Cost components 
comprise 4 main categories (Screening, Intervention Delivery, Supervision, and Other). 
Senior center management and social workers (interventionists) kept detailed logs of 
time spent conducting each component. The cost of conducting the intervention was 
calculated as the time spent performing each task multiplied by wage rate of the 
individual who performed the task. Non-time related cost (material and mileage) was 
also calculated. RESULTS: A total of 166 participants received the intervention. 
Average cost of BTB was $342 per person. The most costly aspect of BTB per person 
was cost of program delivery ($275), followed by materials ($48).The least costly 
aspect of the intervention was time spent supervising interventionists ($9). CONCLU-
SIONS: This study informs decision makers about the resources required for depres-
sion community support interventions, which are not typically reimbursable through 
private or public health care programs. Results can also inform decision making 
regarding the costs of such interventions in relation to pharmacological treatments.
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OBJECTIVES: To analyze the health care utilization by patients diagnosed with major 
depressive disorder (MDD). METHODS: This was a retrospective longitudinal 
descriptive database study of the utilization of health care by patients with MDD from 
the South-West region of Sweden (1.5 million inhabitants). All patients who were 
diagnosed with MDD (ICD-10 F32 or F33) during 2007 were included in the study. 
All costs from health care visits when an MDD was the primary diagnose were 
included as well as all cost from all dispensed antidepressant (ATC N06A) drugs. 
RESULTS: A total of 37,445 patients had at least one health care visit with an MDD 
